FDA, Eli Lilly

Eli Lilly Joins FDA Lawsuit Over Compounded Obesity Drugs, Seeks 'Swift End' And 'To Protect Its Interests'
As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing Facilities Association and FarmaKeio Custom Compounding against the FDA. The court has now ordered the Outsourcing Facilities Association to respond by January 15,
Eli Lilly asks to join FDA in opposing lawsuit from pharmacies
CNBC's Becky Quick reports on news from Eli Lilly. US surgeon general urges cancer warnings for alcoholic drinks 14 Trader Joe's Items That Have Gained a Cult Following for a Good Reason
Lilly looks to 'protect its interests' by moving to join FDA lawsuit over compounded tirzepatide
After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking to protect its investment by wading into a lawsuit that seeks to allow | After plugging $23 billion into its manufacturing network to meet rampant demand for Mounjaro and Zepbound,
Eli Lilly to join lawsuit over GLP-1 shortage: 4 things to know
Eli Lilly is joining in a lawsuit filed by the Outsourcing Facilities against the FDA, aiming to reverse the FDA's October 2024 determination that the shortage has been resolved, which would allow compounding pharmacies to continue selling unapproved versions of the drugs, according to court documents obtained by Becker's .
Lilly Asks to Join GLP-1 Compounding Lawsuit
Eli Lilly’s request to intervene in a suit filed by compounding pharmacies against the FDA reflects a belief the outcome could affect its business and that the FDA does not adequately represent its interests.
Pharma giant seeks to join lawsuit against FDA over weight loss drugs
Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the “entitlement” some pharmacies have practiced in mass-marketing copies of its highly popular GLP-1 medications.
Eli Lilly & Co. stock rises Friday, still underperforms market
Shares of Eli Lilly & Co. LLY inched 0.50% higher to $781.98 Friday, on what proved to be an all-around positive trading ...
Pharmaceutical Technology2h
LY-4052031 by Eli Lilly and Co for Ovarian Cancer: Likelihood of Approval
LY-4052031 is under clinical development by Eli Lilly and Co and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success ...
Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More.
Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...
FiercePharma2d
Roche projected to claim pharma's 2025 sales crown as Novo, Lilly climb rankings: Evaluate
The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...
Pharmaceutical Technology2h
LY-4101174 by Eli Lilly and Co for Prostate Cancer: Likelihood of Approval
LY-4101174 is under development for the treatment of solid tumors, urothelial carcinoma, triple negative breast cancer, non-small cell lung cancer, esophageal cancer, pancreatic c ...
Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.
Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...
Vivienne Scarpellini named 2025 Lawrence County Lilly scholar
The scholarship will pay for 4 years of tuition, fees and books at an Indiana public or private nonprofit college or ...